GME Programs as Master Adaptive Learners: Using Artificial Intelligence Enabled Precision Education and GME Program Milestones to Power Improvement of GME Programs Read more about GME Programs as Master Adaptive Learners: Using Artificial Intelligence Enabled Precision Education and GME Program Milestones to Power Improvement of GME Programs
Defining the Role of ER Stress Proteins in Calcium-Dependent Arrhythmia Read more about Defining the Role of ER Stress Proteins in Calcium-Dependent Arrhythmia
Cystic Fibrosis Learning Center Network Award Read more about Cystic Fibrosis Learning Center Network Award
Inflammatory Bowel Disease West Case Conference Read more about Inflammatory Bowel Disease West Case Conference
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease Read more about Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Read more about An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is Read more about A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Read more about A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers
